Semaglutide and tirzepatide, compared without hype.
This comparison is built to help patients understand the difference in format and decision logic, not to make a treatment promise. The final choice should always come from licensed provider review.
Active route
Semaglutide
GLP-1 pathway
Use this selector to focus the comparison. The table does not answer the question by itself, but it does organize the conversation before the quiz.
- Often recognized by Ozempic® / Wegovy® references
- Weekly injection format
- May be discussed as a steadier starting path
- Still requires provider review
Active comparison
Medication class
Semaglutide: GLP-1 agonist
Tirzepatide: Dual GIP/GLP-1 agonist
How the decision is actually made
The real decision depends on full medical history, prior treatment response, tolerability, goals, current medications, and what a licensed provider considers appropriate.
The next step is still the evaluation
If a patient wants to continue, the right move is not guessing from a chart. It is completing the evaluation so the provider can review the case in context.
Start evaluation